Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. held its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,000 shares of the medical research company’s stock at the end of the 2nd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P.’s holdings in Thermo Fisher Scientific were worth $523,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Waldron LP lifted its stake in shares of Thermo Fisher Scientific by 48.1% during the first quarter. Waldron LP now owns 4,455 shares of the medical research company’s stock valued at $661,000 after buying an additional 1,447 shares during the period. Empire Life Investments Inc. lifted its stake in shares of Thermo Fisher Scientific by 132.0% during the first quarter. Empire Life Investments Inc. now owns 52,504 shares of the medical research company’s stock valued at $7,861,000 after buying an additional 29,875 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of Thermo Fisher Scientific by 27.9% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 28,959 shares of the medical research company’s stock valued at $4,448,000 after buying an additional 6,314 shares during the period. Boston Family Office LLC lifted its stake in shares of Thermo Fisher Scientific by 5.9% during the first quarter. Boston Family Office LLC now owns 19,980 shares of the medical research company’s stock valued at $3,069,000 after buying an additional 1,115 shares during the period. Finally, Mitchell Capital Management Co. lifted its stake in shares of Thermo Fisher Scientific by 27.2% during the first quarter. Mitchell Capital Management Co. now owns 32,030 shares of the medical research company’s stock valued at $4,920,000 after buying an additional 6,842 shares during the period. Institutional investors and hedge funds own 83.32% of the company’s stock.

In related news, Director Jim P. Manzi sold 11,318 shares of the firm’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the completion of the sale, the director now directly owns 38,757 shares in the company, valued at $6,702,635.58. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Seth H. Hoogasian sold 4,140 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the sale, the vice president now owns 25,518 shares of the company’s stock, valued at $4,537,100.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 52,738 shares of company stock valued at $9,302,112. 0.49% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/22/holt-capital-advisors-l-l-c-dba-holt-capital-partners-l-p-continues-to-hold-stake-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Inc (NYSE:TMO) opened at 193.86 on Friday. The firm’s 50-day moving average is $190.66 and its 200-day moving average is $176.57. The stock has a market cap of $75.63 billion, a P/E ratio of 33.77 and a beta of 1.05. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $194.43.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the company posted $2.03 earnings per share. On average, analysts forecast that Thermo Fisher Scientific Inc will post $9.35 EPS for the current year.

Several equities analysts recently issued reports on the stock. Jefferies Group LLC reissued a “hold” rating and set a $195.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective on the stock in a research note on Thursday, September 7th. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley reissued an “overweight” rating and set a $220.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Thermo Fisher Scientific currently has an average rating of “Buy” and an average price target of $203.64.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.